Regeneration of Volumetric Muscle Loss Using MSCs Encapsulated in PRP-Derived Fibrin Microbeads


ŞEKER Ş., LALEGÜL ÜLKER Ö., ELÇİN A. E., ELÇİN Y. M.

Methods in molecular biology (Clifton, N.J.), cilt.2939, ss.221-230, 2025 (Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 2939
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1007/7651_2024_533
  • Dergi Adı: Methods in molecular biology (Clifton, N.J.)
  • Derginin Tarandığı İndeksler: Scopus, Biotechnology Research Abstracts, CAB Abstracts, MEDLINE
  • Sayfa Sayıları: ss.221-230
  • Anahtar Kelimeler: Blood-derived materials, Cell encapsulation, Fibrin, Mesenchymal stem cells, Musculoskeletal biology, Personalized medicine, Platelet-rich plasma, Regenerative medicine, Skeletal muscle injury, Tissue engineering, Volumetric muscle loss
  • Ankara Üniversitesi Adresli: Evet

Özet

Volumetric muscle loss (VML) is one of the major types of soft tissue injury frequently encountered worldwide. In case of VML, the endogenous regenerative capacity of the skeletal muscle tissue is usually not sufficient for complete healing of the damaged area resulting in permanent functional musculoskeletal impairment. Therefore, the development of new tissue engineering approaches that will enable functional skeletal muscle regeneration by overcoming the limitations of current clinical treatments for VML injuries has become a critical goal. Platelet-rich plasma (PRP) is an inexpensive and relatively effective blood product with a high concentration of platelets containing various growth factors and cytokines involved in wound healing and tissue regeneration. Due to its autologous nature, PRP has been a safe and widely used treatment option for various wound types for many years. Recently, PRP-based biomaterials have emerged as a promising approach to promote muscle tissue regeneration upon injury. This chapter describes the use of PRP-derived fibrin microbeads as a versatile encapsulation matrix for the localized delivery of mesenchymal stem cells and growth factors to treat VML using tissue engineering strategies.